<DOC>
	<DOCNO>NCT00140140</DOCNO>
	<brief_summary>The purpose study : 1 ) determine optimal tolerate dose ABI-007 vinorelbine , give concurrently weekly basis , absence plan growth factor support granulocyte colony-stimulating factor ( G-CSF ) ( Patients HER-2/neu positive disease may receive Herceptin , 2 ) determine optimal tolerate dose ABI-007 vinorelbine , give concurrently weekly basis , presence plan growth factor support G-CSF .</brief_summary>
	<brief_title>A Phase I/II Study ABI-007 ( Abraxane® , Nab®-Paclitaxel ) Vinorelbine Patients With Stage IV ( Metastatic ) Breast Cancer</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Vinorelbine</mesh_term>
	<mesh_term>Vinblastine</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Trastuzumab</mesh_term>
	<mesh_term>Lenograstim</mesh_term>
	<criteria>Patient microscopically confirm invasive breast carcinoma clinical and/or radiographic evidence stage 4 disease . If diagnosis base pleural effusion , positive cytology must confirm . Patient prior chemotherapy Stage 4 disease ( hormone therapy permit ) . Prior adjuvant paclitaxel 3hour infusion permit , residual neuropathy . Prior adjuvant docetaxel every 3 week schedule permit . Disease must measurable ( unidimensional Response Evaluation Criteria In Solid Tumors ( RECIST ) criterion ) evaluable ( e.g. , malignant effusion , marrow involvement ) . Elevated tumor marker alone insufficient . Age &gt; 18 . Southwest Oncology Group ( SWOG ) /Eastern Oncology Group ( ECOG ) performance status must &lt; =2 screen treatment day one . Life expectancy must estimate &gt; 16 week . Prior irradiation permit , provide : Does exceed 25 % estimate bone marrow volume Measurable/evaluable disease exist outside radiation field , progressive disease document within radiation field . Informed consent must obtain prior registration . Patients must &gt; 2 week prior surgery ; &gt; 3 week radiation therapy pelvis , spine long bone ; &gt; 3 week prior chemotherapy ( &gt; 6 week mitomycin C nitrosureas ) , &gt; 2 week prior hormonal therapy . All patient must placement appropriate central venous access device . Tumor HER2/neu expression must determine prior study enrollment . Assessment may fluorescence situ hybridization ( FISH ) assay immunohistochemistry ( ICC ) . If determination intermediate ICC , FISH must perform . For enrollment purpose , phase I study discriminate base HER2 status . However , documentation patient ' HER2 status maintain Herceptin prescribe HER2 positive patient . Granulocytes &lt; 1,500/mm^3 . Platelets &lt; 100,000/mm^3 . Hemoglobin &lt; 9 gm/dl . Creatinine &gt; 2.0 mg/dl . Total bilirubin &gt; 2 mg/dl . Visceral crisis characterize rapidly progressive hepatic lymphangitic lung metastasis . Medically unstable judge patient 's physician . Pregnancy lactation ; failure employ adequate contraception . Uncontrolled central nervous system ( CNS ) disease . Preexisting Grade ≥ 2 peripheral neuropathy except abnormality due cancer . Psychological , familial , sociological geographical condition permit weekly medical followup compliance study protocol . Prior therapy vinorelbine prior therapy taxane result neuropathy .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2013</verification_date>
	<keyword>Breast cancer</keyword>
</DOC>